Abstract: The present invention is directed to cancer cell traps and methods of using cancer cell traps to treat and detect metastatic cancer in subjects. The cancer cell traps are administered to subjects and induce the migration and accumulation of metastatic cancer cells in the cancer cell traps.
Type:
Grant
Filed:
October 19, 2013
Date of Patent:
August 16, 2022
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
Type:
Grant
Filed:
April 26, 2019
Date of Patent:
July 12, 2022
Assignee:
NOVO NORDISK A/S
Inventors:
Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
Abstract: The present disclosure provides for methods and compositions for the modulation of CD5 in a subject. Also provided are methods of detecting and monitoring diseases, such as inflammatory and autoimmune diseases.
Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
June 14, 2022
Assignee:
Genexine, Inc.
Inventors:
Moon Cheol Kang, Young Woo Choi, Donghoon Choi, Young Chul Sung
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
June 7, 2022
Assignee:
Astute Medical, Inc.
Inventors:
James Patrick Kampf, Paul McPherson, Donald Chalfin
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Metalloproteinase inhibitor 1, Metalloproteinase inhibitor 2, Metalloproteinase inhibitor 4, C—C motif chemokine 15, C—C motif chemokine 18, C—C motif chemokine 23, and/or, C—C motif chemokine 24 as diagnostic and prognostic biomarker assays in renal injuries.
Type:
Grant
Filed:
February 6, 2018
Date of Patent:
May 31, 2022
Assignee:
Astute Medical, Inc.
Inventors:
Joseph Anderberg, Paul McPherson, James Patrick Kampf, Kevin Nakamura, Jeff Gray, Thomas Kwan
Abstract: The inventions relate to the use of hemichannel blockers to modulate cytokine levels in a subject, including the angiogenic cytokine, VEGF, and their production, secretion and/or release, and to the use of hemichannel blockers to reduce or level cytokine activity, including in conditions characterized in whole or in part by angiogenesis and/or vessel leak.
Type:
Grant
Filed:
July 19, 2018
Date of Patent:
May 31, 2022
Assignees:
AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC.
Inventors:
Colin Richard Green, Odunayo Omolola Boluwarin Mugisho, Bradford James Duft
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C—C motif chemokine 16, C—C motif chemokine 14, and Tyrosine-protein kinase receptor UFO as diagnostic and prognostic biomarker assays in renal injuries.
Type:
Grant
Filed:
October 20, 2015
Date of Patent:
May 17, 2022
Assignee:
ASTUTE MEDICAL, INC.
Inventors:
Joseph Anderberg, Paul McPherson, Jeff Gray, Kevin Nakamura, James Patrick Kampf, Thomas Kwan
Abstract: Methods of treating fibrotic diseases and disorders including Systemic sclerosis (SSc) are provided. Methods include, for example, administering to a subject an effective amount of an antagonist/inhibitor of PTP4A1 protein expression or activity to treat a fibrotic disease or disorder such as SSc, or an associated pathology such as organ or skin fibrosis.
Type:
Grant
Filed:
September 6, 2016
Date of Patent:
May 17, 2022
Assignee:
LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
Inventors:
Nunzio Bottini, Cristiano Sacchetti, Stephanie M. Stanford
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
Type:
Grant
Filed:
November 7, 2017
Date of Patent:
May 17, 2022
Assignee:
Neuracle Science Co., Ltd.
Inventors:
Bongcheol Kim, Jae Young Seong, Jong Ik Hwang, Eun Bee Cho, Junho Chung, Junyeong Jin, Tae Young Yune, Jee Youn Lee
Abstract: The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
Type:
Grant
Filed:
August 24, 2018
Date of Patent:
April 19, 2022
Assignee:
RANI THERAPEUTICS, LLC
Inventors:
Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
Abstract: Methods and compositions for reducing the activity or number of memory Th17 cells in ocular tissue, and for treatment and/or prevention of ocular immunoinflammatory diseases are described.
Type:
Grant
Filed:
January 6, 2017
Date of Patent:
April 19, 2022
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
Type:
Grant
Filed:
July 31, 2018
Date of Patent:
April 5, 2022
Assignee:
RANI THERAPEUTICS, LLC
Inventors:
Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
Abstract: Methods for identifying and treating patients having cancer who are likely to respond to treatment with an anti-CD37 immunoconjugate (e.g., IMGN529) are provided.
Type:
Grant
Filed:
November 2, 2017
Date of Patent:
March 22, 2022
Assignee:
DEBIOPHARM INTERNATIONAL, S.A.
Inventors:
Francesco Bertoni, Angela Romanelli, Callum Sloss
Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.
Type:
Grant
Filed:
May 2, 2019
Date of Patent:
March 22, 2022
Assignee:
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Inventors:
Matthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'Neill
Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
March 1, 2022
Assignee:
MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Inventors:
Satish Nadig, Carl Atkinson, Ann-Marie Broome, Suraj K. Dixit
Abstract: Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.
Type:
Grant
Filed:
February 12, 2018
Date of Patent:
March 1, 2022
Assignee:
INSTITUTE FOR CANCER RESEARCH
Inventors:
Roland L. Dunbrack, Jared Adolf-Bryfogle, Gregory P. Adams, Matthew K. Robinson
Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
Type:
Grant
Filed:
July 12, 2013
Date of Patent:
February 8, 2022
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
Inventors:
Jerome Galon, Franck Pages, Bernard Mlecnik, Gabriela Bindea
Abstract: The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
February 8, 2022
Assignee:
The Schepens Eye Research Institute, Inc.